Plain Language Summary: POETYK PSO-1 study, treatment of plaque psoriasis with deucravacitinib
This Plain Language Summary from Immunotherapy summarises a study called POETYK PSO-1. The study looked at a new treatment called deucravacitinib for a skin condition called plaque psoriasis.
Read the full article here.
Play the video below to see the author giving an overview of the PLSP.
The original article which this summary is based on is called ‘Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial’, published in the Journal of the American Academy of Dermatology. Read the original article here.